Identification of NSAID users at risk for gastrointestinal complications: A systematic review of current guidelines and consensus agreements

Drug Safety

Volumn 33, Issue 6, 2010, Pages 443-453

  Tielemans, Merel M ^a   Eikendal, Ties ^a   Jansen, Jan B M J ^a   Van Oijen, Martijn G H ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticoagulants, general; Aspirin, adverse reactions; Corticosteroids, general; Cyclo oxygenase 2 inhibitors, adverse reactions; Gastrointestinal disorders, general; Helicobacter pylori infections, general

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CORTICOSTEROID; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR;

AGING; ANTICOAGULANT THERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONSENSUS; DRUG USE; GASTROINTESTINAL DISEASE; HELICOBACTER INFECTION; HUMAN; LOW DRUG DOSE; MEDLINE; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL PROTOCOLS; CONSENSUS; GASTROINTESTINAL DISEASES; GUIDELINES AS TOPIC; HUMANS; NONPRESCRIPTION DRUGS; RISK FACTORS;

EID: 77952841800     PISSN: 01145916     EISSN: 11791942     Source Type: Journal    
DOI: 10.2165/11534590-000000000-00000     Document Type: Review

References (46)

1. Hawkey CJ, Langman MJ. Non-steroidal anti-inflammatory drugs: overall risks and management. Complementary roles for COX-2 inhibitors and proton pump inhibitors, Gut, 2003 Apr, 52, 4, 600-608
2. Hernandez-Diaz S, Garcia-Rodriguez LA. Epidemiologic assessment of the safety of conventional nonsteroidal anti-inflammatory drugs. Am J Med 2001 Feb 19; 110 Suppl. 3A: 20-7S
3. Jones R, Rubin G, Berenbaum F, et al. Gastrointestinal and cardiovascular risks of nonsteroidal anti-inflammatory drugs. Am J Med 2008 Jun; 121 (6): 464-474
4. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999 Jun 17; 340 (24): 1888-1899
5. Lanas A, Hirschowitz BI. Toxicity of NSAIDs in the stomach and duodenum. Eur J Gastroenterol Hepatol 1999 Apr; 11 (4): 375-381
6. Ofman JJ, Maclean CH, Straus WL, et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum 2003 Aug 15; 49 (4): 508-518
7. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study. A randomized controlled trial. Celecoxib Long-Term Arthritis Safety Study. JAMA 2000 Sep 13; 284 (10): 1247-1255
8. Watson DJ, Harper SE, Zhao PL, et al. Gastrointestinal tolerability of the selective cyclooxygenase-2 (COX-2) in-hibitor rofecoxib compared with nonselective COX-1 and COX-2 inhibitors in osteoarthritis. Arch Int Med 2000 Oct 23; 160 (19): 2998-3003
9. Larkai EN, Smith JL, Lidsky MD, et al. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol 1989 Apr; 11 (2): 158-162
10. Bombardier C, Laine L, Reicin A, et al. Comparison of up-per gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000 Nov 23; 343 (21): 1520-1528
11. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001 Feb; 120 (3): 594-606
12. American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Antiin-flammatory Drugs. Recommendations for use of selective and nonselective nonsteroidal antiinflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum, 2008 Aug 15, 59 (8) 1058-1073
13. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Am J Gastroenterol 2008 Nov; 103 (11): 2890-2907
14. Chan FK, Abraham NS, Scheiman JM, et al. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents. Am J Gastroenterol 2008 Nov; 103 (11): 2908-2918
15. Dubois RW, Melmed GY, Henning JM, et al. Guidelines for the appropriate use of non-steroidal anti-inflammatory drugs, cyclo-oxygenase-2-specific inhibitors and proton pump inhibitors in patients requiring chronic anti-inflammatory therapy. Aliment Pharmacol Ther 2004 Jan 15; 19 (2): 197-208
16. Lanza FL, Chan FK, Quigley EM. Guidelines for preven-tion of NSAID-related ulcer complications. Am J Gastro-enterol 2009 Mar; 104 (3): 728-738
17. Rostom A, Moayyedi P, Hunt R. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks. Aliment Pharmacol Ther 2009 Mar 1; 29 (5): 481-496
18. Schoenfeld P, Kimmey MB, Scheiman J, et al. Review arti-cle: nonsteroidal anti-inflammatory drug-associated gastrointestinal complications: guidelines for prevention and treatment. Aliment Pharmacol Ther 1999 Oct; 13 (10): 1273-1285
19. Targownik LE, Thomson PA. Gastroprotective strategies among NSAID users: guidelines for appropriate use in chronic illness. Can Fam Physician 2006 Sep; 52 (9): 1100-1105
20. Wilcox CM, Allison J, Benzuly K, et al. Consensus devel-opment conference on the use of nonsteroidal anti-inflammatory agents, including cyclooxygenase-2 enzyme inhibitors and aspirin. Clin Gastroenterol Hepatol 2006 Sep; 4 (9): 1082-1089
21. Lanas A. Economic analysis of strategies in the prevention of non-steroidal anti-inflammatory drug-induced complications in the gastrointestinal tract. Aliment Pharmacol Ther 2004 Aug 1; 20 (3): 321-331
22. Motola D, Vaccheri A, Silvani MC, et al. Pattern of NSAID use in the Italian general population: a questionnaire-based survey. Eur J Clin Pharmacol 2004 Dec; 60 (10): 731-738
23. Kiltz U, Zochling J, Schmidt WE, et al. Use of NSAIDs and infection with Helicobacter pylori: what does the rheuma-tologist need to know? Rheumatology (Oxford) 2008 Sep; 47 (9): 1342-1347
24. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helico-bacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001 Mar 29; 344 (13): 967-973
25. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal anti-inflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998 Sep 26; 352 (9133): 1016-1021
26. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for ser-ious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med 1991 Nov 15; 115 (10): 787-796
27. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995 Aug 15; 123 (4): 241-249
28. Schoen RT, Vender RJ. Mechanisms of nonsteroidal anti-inflammatory drug-induced gastric damage. Am J Med 1989 Apr; 86 (4): 449-458
29. McQuaid KR, Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 2006 Aug; 119 (8): 624-638
30. Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995 Apr 1; 310 (6983): 827-830
31. Serrano P, Lanas A, Arroyo MT, et al. Risk of upper gas-trointestinal bleeding in patients taking low-dose aspirin for the prevention of cardiovascular diseases. Aliment Pharmacol Ther 2002 Nov; 16 (11): 1945-1953
32. Lanas A, Garcia-Rodriguez LA, Arroyo MT, et al. Risk of upper gastrointestinal ulcer bleeding associated with selective cyclo-oxygenase-2 inhibitors, traditional non-aspirin non-steroidal anti-inflammatory drugs, aspirin and combinations. Gut 2006 Dec; 55 (12): 1731-1738
33. Chan FK, To KF, Wu JC, et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002 Jan 5; 359 (9300): 9-13
34. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002 Jan 5; 359 (9300): 14-22
35. Leontiadis GI, Sreedharan A, Dorward S, et al. Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding. Health Technol Assess 2007 Dec; 11 (51): iii-164
36. Chan FK, Ching JY, Hung LC, et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005 Jan 20; 352 (3): 238-244
37. Hallas J, Dall M, Andries A, et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006 Oct 7; 333 (7571): 726
38. Ho PM, Maddox TM, Wang L, et al. Risk of adverse out-comes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009 Mar 4; 301 (9): 937-944
39. Juurlink DN, Gomes T, Ko DT, et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009 Mar 31; 180 (7): 713-718
40. Ng FH, Wong BC, Wong SY, et al. Clopidogrel plus ome-prazole compared with aspirin plus omeprazole for aspirin-induced symptomatic peptic ulcers/erosions with low to moderate bleeding/re-bleeding risk: a single-blind, randomized controlled study. Aliment Pharmacol Ther 2004 Feb 1; 19 (3): 359-365
41. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastro-intestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther 2008 Jan 1; 27 (1): 31-40
42. Henry D, Lim LL, Garcia Rodriguez LA, et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996 Jun 22; 312 (7046): 1563-1566
43. Gutthann SP, Garc?a Rodriguez LA, Raiford DS. In-dividual nonsteroidal antiiflammatory drugs and other risk factors for upper gastrointestinal bleeding and perforation. Epidemiology 1997 Jan; 8 (1): 18-24
44. French DP, James DH. Reasons for the use of mild analge-sics among English students. Pharm World Sci 2008 Jan; 30 (1): 79-85
45. Lewis JD, Kimmel SE, Localio AR, et al. Risk of serious upper gastrointestinal toxicity with over-the-counter non-aspirin nonsteroidal anti-inflammatory drugs. Gastro-enterology 2005 Dec; 129 (6): 1865-1874
46. Tarone RE, Blot WJ, McLaughlin JK. Nonselective non-aspirin nonsteroidal anti-inflammatory drugs and gastrointestinal bleeding: relative and absolute risk estimates from recent epidemiologic studies. Am J Ther 2004 Jan-Feb; 11 (1): 17-25